Fortress Biotech (FBIO) CFO David Jin Buys 400,000 Shares

David Jin, the Chief Financial Officer of FBIO, bought 400,000 shares of the company on June 22, 2026. This insider transaction did not involve a set purchase price, as the shares were acquired at zero cost. Jin's purchase reflects a notable vote of confidence in the company.

Other Institutional Activity in FBIO

Several institutional investors have also shown interest in FBIO. Vanguard Capital Management LLC opened a new position with 966,030 shares, valued at approximately $2.7 million. OPALEYE MANAGEMENT INC. reduced its holdings by 48,000 shares, leaving it with 1,042,000 shares worth about $2.9 million, a 4.4% decrease. Meanwhile, SHIKIAR ASSET MANAGEMENT INC. increased its stake by 27,000 shares, ending with 305,469 shares valued at $852,000, representing a 9.7% increase. GEODE CAPITAL MANAGEMENT, LLC also boosted its position by 27,763 shares, holding a total of 290,255 shares worth $810,110, a 10.6% increase.

Fortress Biotech, Inc. Stock Up 25.1%

Shares of FBIO traded near $3.14 on Thursday. The company is drawing attention from both insiders and institutional investors, which could impact market perceptions. Although detailed financial metrics like market cap and P/E ratio aren't provided, the stock's recent activity suggests it is under close watch by various stakeholders.

Insider Buying and Selling at Fortress Biotech, Inc.

In addition to David Jin's recent purchase, several other insiders have been active this year. On March 18, 2026, both Lindsay Rosenwald, President, CEO & Chairman, and Michael Weiss, Executive Vice Chairman, each acquired 475,424 shares. Earlier in the year, on January 1, insiders Malcolm Hoenlein, Jay Lobell, and Jimmie Harvey each bought 27,322 shares. None of these transactions were conducted under a pre-arranged trading plan.

Analysts Set New Price Targets

Analyst activity has been robust for FBIO, with HC Wainwright & Co. reiterating a 'buy' rating and a $17 price target as recently as February 23, 2026. This follows a series of consistent 'buy' ratings from the firm, reflecting a positive outlook. Roth MKM also reiterated a 'buy' rating with a $16 target back in March 2025.

Bottom Line

David Jin's purchase of 400,000 shares is a significant insider move, signaling his confidence in FBIO's prospects. The company's stock, trading at $3.14, has seen varied activity from institutional investors, suggesting a keen interest in its performance. Analyst ratings further underscore a positive sentiment, though investors should remember that these transactions and ratings are backward-looking and may not indicate future performance.